Table of Contents
1.1 List of Tables 5
1.2 List of Figures 9
2 Introduction 10
2.1 Bioabsorbable Stents (BAS) Overview 10
3 Products under Development 11
3.1 Bioabsorbable Stents (BAS) – Pipeline Products by Stage of Development 11
3.2 Bioabsorbable Stents (BAS) – Pipeline Products by Territory 12
3.3 Bioabsorbable Stents (BAS) – Pipeline Products by Regulatory Path 13
3.4 Bioabsorbable Stents (BAS) – Pipeline Products by Estimated Approval Date 14
3.5 Bioabsorbable Stents (BAS) – Ongoing Clinical Trials 15
4 Bioabsorbable Stents (BAS) – Pipeline Products under Development by Companies 16
4.1 Bioabsorbable Stents (BAS) Companies – Pipeline Products by Stage of Development 16
4.2 Bioabsorbable Stents (BAS) – Pipeline Products by Stage of Development 18
5 Bioabsorbable Stents (BAS) Companies and Product Overview 20
5.1 Abbott Vascular Inc Company Overview 20
5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 20
5.2 Amaranth Medical Inc Company Overview 21
5.2.1 Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 21
5.3 Arterius Ltd Company Overview 30
5.3.1 Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
5.4 Biosensors International Group Ltd Company Overview 31
5.4.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 31
5.5 Biosten, LLC Company Overview 32
5.5.1 Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview 32
5.6 Biotronik AG Company Overview 33
5.6.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview 33
5.7 Biotronik SE & Co KG Company Overview 43
5.7.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 43
5.8 Boston Scientific Corp Company Overview 44
5.8.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 44
5.9 Cardionovum GmbH Company Overview 49
5.9.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 49
5.10 Cordis Corp Company Overview 50
5.10.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 50
5.11 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 51
5.11.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 51
5.12 Icon Interventional Systems, Inc. Company Overview 52
5.12.1 Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 52
5.13 Japan Stent Technology Co., Ltd. Company Overview 53
5.13.1 Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
5.14 Kyoto Medical Planning Co Ltd Company Overview 54
5.14.1 Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
5.15 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 55
5.15.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 55
5.16 Manli Cardiology Ltd Company Overview 58
5.16.1 Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview 58
5.17 Micell Technologies Inc Company Overview 59
5.17.1 Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 59
5.18 Michigan Technological University Company Overview 64
5.18.1 Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview 64
5.19 MicroPort Scientific Corp Company Overview 65
5.19.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 65
5.20 Minvasys SAS Company Overview 69
5.20.1 Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview 69
5.21 MIV Therapeutics Inc Company Overview 70
5.21.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 70
5.22 NanoCoeur, Inc. Company Overview 72
5.22.1 NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 72
5.23 North Carolina State University Company Overview 73
5.23.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 73
5.24 Northwestern University Company Overview 74
5.24.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 74
5.25 OrbusNeich Company Overview 75
5.25.1 OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 75
5.26 Pediastent LLC Company Overview 77
5.26.1 Pediastent LLC Pipeline Products & Ongoing Clinical Trials Overview 77
5.27 QualiMed Innovative Medizinprodukte GmbH Company Overview 78
5.27.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview 78
5.28 REVA Medical Inc Company Overview 79
5.28.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 79
5.29 S3V Vascular Technologies Company Overview 84
5.29.1 S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview 84
5.30 Tepha Inc Company Overview 85
5.30.1 Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview 85
5.31 University of Alabama at Birmingham Company Overview 86
5.31.1 University of Alabama at Birmingham Pipeline Products & Ongoing Clinical Trials Overview 86
5.32 University of Florida Company Overview 87
5.32.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 87
5.33 University of Strathclyde Company Overview 88
5.33.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview 88
5.34 VasoTech Inc. Company Overview 89
5.34.1 VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview 89
5.35 Xenogenics Corporation Company Overview 90
5.35.1 Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 90
6 Bioabsorbable Stents (BAS)- Recent Developments 93
6.1 Nov 06, 2019: Final five unpublished late-breaking clinical trial results announced at VIVA19 93
6.2 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 95
6.3 Sep 20, 2019: Terumo to increase production capacity for alliance business 97
6.4 Aug 29, 2019: MicroPort announces interim results for the six months ended June 30, 2019 98
6.5 Aug 28, 2019: Boston Scientific Celebrates 15th Anniversary in Costa Rica 100
7 Appendix 116
7.1 Methodology 116
7.2 About GlobalData 119
7.3 Contact Us 119
7.4 Disclaimer 119
Table 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
Table 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
Table 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
Table 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
Table 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
Table 6: Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
Table 7: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
Table 8: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Second Generation Bioresorbable Vascular Scaffold - Product Status
Table 10: Second Generation Bioresorbable Vascular Scaffold - Product Description
Table 11: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Status
Table 13: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Description
Table 14: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
Table 15: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
Table 16: DEFIANCE Scaffold - Product Status
Table 17: DEFIANCE Scaffold - Product Description
Table 18: FORTITUDE Scaffold - Product Status
Table 19: FORTITUDE Scaffold - Product Description
Table 20: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
Table 21: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
Table 22: Second Generation FORTITUDE Scaffold - Product Status
Table 23: Second Generation FORTITUDE Scaffold - Product Description
Table 24: Amaranth Medical Inc - Ongoing Clinical Trials Overview
Table 25: FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold
Table 26: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial
Table 27: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II
Table 28: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III
Table 29: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 30: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
Table 31: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
Table 32: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 33: Sparrow Drug Eluting Stent System - Product Status
Table 34: Sparrow Drug Eluting Stent System - Product Description
Table 35: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 36: Biodegradable Endovascular Implant - Product Status
Table 37: Biodegradable Endovascular Implant - Product Description
Table 38: Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
Table 39: Magmaris Bioresorbable Magnesium Scaffold - Product Status
Table 40: Magmaris Bioresorbable Magnesium Scaffold - Product Description
Table 41: Magmaris Bioresorbable Magnesium Scaffold - 3rd Generation - Product Status
Table 42: Magmaris Bioresorbable Magnesium Scaffold - 3rd Generation - Product Description
Table 43: Biotronik AG - Ongoing Clinical Trials Overview
Table 44: Magmaris Bioresorbable Magnesium Scaffold - A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II
Table 45: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
Table 46: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIKS - Acute Performance of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-III
Table 47: Magmaris Bioresorbable Magnesium Scaffold - Biotroniks - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV
Table 48: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIKS-Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris (BIOSOLVE)-IV Magmaris Swiss Satellite Registry
Table 49: Magmaris Bioresorbable Magnesium Scaffold - Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI)
Table 50: Magmaris Bioresorbable Magnesium Scaffold - Magnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients with Acute ST Segment Elevation Myocardial Infarction
Table 51: Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction with the Drug-eluting Resorbable Magnesium Scaffold: The BEST- MAG Multicentre Study (Belgian ST-segment Elevation Myocardial Infarction Treatment with Resorbable Magnesium Scaffold)
Table 52: Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Tomography Evaluation of Bioabsorbable Vascular Scaffold Technique with Magmaris
Table 53: Magmaris Bioresorbable Magnesium Scaffold - Prospective Observational Registry of Patients with a Bioabsorbable Magnesium Stent Implant -MAGMARIS- in Usual Clinical Practice
Table 54: Magmaris Bioresorbable Magnesium Scaffold - Retrospective, Observational Register to Investigate the Procedural and Post Procedural Implantation of Bioabsorbable Magnesium Scaffolds MAGMARIS (MAGIC Registry)
Table 55: Magmaris Bioresorbable Magnesium Scaffold - Scaffold Implantation in Emilia-Romagna
Table 56: Magmaris Bioresorbable Magnesium Scaffold - 3rd Generation - BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries
Table 57: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
Table 58: AMS-2 - Product Status
Table 59: AMS-2 - Product Description
Table 60: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 61: Fully Resorbable Drug-Eluting Scaffold System - Product Status
Table 62: Fully Resorbable Drug-Eluting Scaffold System - Product Description
Table 63: SYNERGY DES 4.5/5.0 - Product Status
Table 64: SYNERGY DES 4.5/5.0 - Product Description
Table 65: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 66: SYNERGY DES 4.5/5.0 - A U.S. Post-approval Study of the SYNERGY 4.50/5.00 mm Everolimus-eluting Platinum Chromium Coronary Stent System (Evolve 4.5/5.0)
List of Figures
Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
Figure 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
Figure 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
Figure 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
Figure 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
【免責事項】
https://www.marketreport.jp/reports-disclaimer